Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Sells $15,600.00 in Stock

Century Therapeutics, Inc. (NASDAQ:IPSC) insider Gregory Russotti sold 5,000 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $3.12, for a total transaction of $15,600.00. Following the completion of the sale, the insider now owns 292,319 shares of the company’s stock, valued at approximately $912,035.28. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Gregory Russotti also recently made the following trade(s):

• On Monday, April 22nd, Gregory Russotti sold 5,000 shares of Century Therapeutics stock. The stock was sold at an average price of $3.10, for a total value of $15,500.00.

Century Therapeutics Stock Down 1.0 %

IPSC opened at $3.04 on Friday. The firm has a market cap of $197.05 million, a P/E ratio of -1.34 and a beta of 1.44. Century Therapeutics, Inc. has a 52 week low of $1.28 and a 52 week high of $5.51. The business has a fifty day simple moving average of $3.88 and a 200-day simple moving average of $3.23.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Thursday, March 14th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.07. Century Therapeutics had a negative return on equity of 54.73% and a negative net margin of 6,115.12%. The company had revenue of $0.27 million during the quarter, compared to the consensus estimate of $1.69 million. Sell-side analysts expect that Century Therapeutics, Inc. will post -1.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $9.00 price objective (down from $10.00) on shares of Century Therapeutics in a report on Friday, April 12th. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Century Therapeutics in a report on Friday, March 15th. Finally, Canaccord Genuity Group boosted their price objective on shares of Century Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a report on Friday, March 15th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $13.60.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Century Therapeutics in the first quarter valued at approximately $47,000. Abel Hall LLC purchased a new stake in shares of Century Therapeutics in the 4th quarter valued at approximately $33,000. Avidity Partners Management LP raised its holdings in shares of Century Therapeutics by 23.4% in the 4th quarter. Avidity Partners Management LP now owns 1,355,000 shares of the company’s stock valued at $4,499,000 after purchasing an additional 256,500 shares in the last quarter. Finally, Federated Hermes Inc. lifted its position in shares of Century Therapeutics by 0.4% during the 4th quarter. Federated Hermes Inc. now owns 618,482 shares of the company’s stock worth $2,053,000 after purchasing an additional 2,500 shares during the last quarter. 50.20% of the stock is currently owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.